

Reza Sari Motlagh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4224853/publications.pdf>

Version: 2024-02-01

80
papers

867
citations

567281

15
h-index

713466

21
g-index

81
all docs

81
docs citations

81
times ranked

770
citing authors

#	ARTICLE	IF	CITATIONS
1	Intravesical Therapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis of Disease Recurrence. <i>European Urology Focus</i> , 2022, 8, 447-456.	3.1	3
2	A panel of systemic inflammatory response biomarkers for outcome prediction in patients treated with radical cystectomy for urothelial carcinoma. <i>BJU International</i> , 2022, 129, 182-193.	2.5	16
3	Accuracy and Clinical Utility of a Tumor Grade- and Stage-based Predictive Model in Localized Upper Tract Urothelial Carcinoma. <i>European Urology Focus</i> , 2022, 8, 761-768.	3.1	10
4	Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 85-95.	4.2	6
5	Accuracy of Frozen Section Analysis of Urethral and Ureteral Margins During Radical Cystectomy for Bladder Cancer: A Systematic Review and Diagnostic Meta-Analysis. <i>European Urology Focus</i> , 2022, 8, 752-760.	3.1	8
6	Androgen receptor axis-targeted agents for non-metastatic castration-resistant prostate cancer impact on overall survival and safety profile. <i>Minerva Urology and Nephrology</i> , 2022, 74, .	2.5	2
7	The Efficacy and Safety of Relugolix Compared with Degarelix in Advanced Prostate Cancer Patients: A Network Meta-analysis of Randomized Trials. <i>European Urology Oncology</i> , 2022, 5, 138-145.	5.4	6
8	Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis. <i>BJU International</i> , 2022, 129, 423-433.	2.5	37
9	Choosing the Most Efficacious and Safe Oral Treatment for Idiopathic Overactive Bladder: A Systematic Review and Network Meta-analysis. <i>European Urology Focus</i> , 2022, 8, 1072-1089.	3.1	14
10	Association between SARS-CoV-2 infection and disease severity among prostate cancer patients on androgen deprivation therapy: a systematic review and meta-analysis. <i>World Journal of Urology</i> , 2022, 40, 907-914.	2.2	19
11	Preoperative plasma level of endoglin as a predictor for disease outcomes after radical cystectomy for nonmetastatic urothelial carcinoma of the bladder. <i>Molecular Carcinogenesis</i> , 2022, 61, 5-18.	2.7	6
12	Comparison of Clinicopathologic and Oncological Outcomes Between Transurethral En Bloc Resection and Conventional Transurethral Resection of Bladder Tumor: A Systematic Review, Meta-Analysis, and Network Meta-Analysis with Focus on Different Energy Sources. <i>Journal of Endourology</i> , 2022, 36, 535-547.	2.1	11
13	Discordance Between Clinical and Pathological Staging and Grading in Upper Tract Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 95.e1-95.e6.	1.9	20
14	Selection and evaluation of preoperative systemic inflammatory response biomarkers model prior to cytoreductive nephrectomy using a machine-learning approach. <i>World Journal of Urology</i> , 2022, 40, 747-754.	2.2	4
15	Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis. <i>International Journal of Clinical Oncology</i> , 2022, 27, 59-71.	2.2	19
16	Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 3091-3102.	2.5	2
17	Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103570.	4.4	11
18	Prognostic effect of preoperative systemic immune-inflammation index in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>Minerva Urology and Nephrology</i> , 2022, 74, .	2.5	8

#	ARTICLE	IF	CITATIONS
19	The Value of Preoperative Plasma VEGF Levels in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. <i>European Urology Focus</i> , 2022, 8, 972-979.	3.1	3
20	En Bloc Resection for Bladder Tumors: An Updated Systematic Review and Meta-Analysis of Its Differential Effect on Safety, Recurrence and Histopathology. <i>Journal of Urology</i> , 2022, 207, 754-768.	0.4	26
21	Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy. <i>European Urology Oncology</i> , 2022, 5, 120-124.	5.4	6
22	Comparison of short-term and long-term neoadjuvant hormone therapy prior to radical prostatectomy: a systematic review and meta-analysis. <i>Scandinavian Journal of Urology</i> , 2022, 56, 85-93.	1.0	3
23	Radiation therapy compared to radical prostatectomy as first-line definitive therapy for patients with high-risk localised prostate cancer: An updated systematic review and meta-analysis. <i>Arab Journal of Urology Arab Association of Urology</i> , 2022, 20, 71-80.	1.5	2
24	Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy. <i>Annals of Surgical Oncology</i> , 2022, 29, 5307-5316.	1.5	6
25	Reassessment of the Efficacy of Carboplatin for Metastatic Urothelial Carcinoma in the Era of Immunotherapy: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2022, 8, 1687-1695.	3.1	10
26	Prognostic impact of insulin-like growth factor and its binding proteins, insulin-like growth factor binding protein and , on adverse histopathological features and survival outcomes after radical cystectomy. <i>International Journal of Urology</i> , 2022, , .	1.0	3
27	Comparative Outcomes of Primary Versus Recurrent High-risk Non-muscle-invasive and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical Cystectomy: Results from a Retrospective Multicenter Study. <i>European Urology Open Science</i> , 2022, 39, 14-21.	0.4	7
28	The effect of immune checkpoint inhibitor combination therapies in metastatic renal cell carcinoma patients with and without previous cytoreductive nephrectomy: A systematic review and meta-analysis. <i>International Immunopharmacology</i> , 2022, 108, 108720.	3.8	13
29	The placebo and nocebo effects in functional urology. <i>Nature Reviews Urology</i> , 2022, 19, 171-189.	3.8	5
30	Influence of steep Trendelenburg position on postoperative complications: a systematic review and meta-analysis. <i>Journal of Robotic Surgery</i> , 2022, 16, 1233-1247.	1.8	6
31	Accuracy of SelectMDx compared to mpMRI in the diagnosis of prostate cancer: a systematic review and diagnostic meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 187-198.	3.9	7
32	Hematological prognosticators in metastatic renal cell cancer treated with immune checkpoint inhibitors: a meta-analysis. <i>Immunotherapy</i> , 2022, 14, 709-725.	2.0	10
33	Quality indicators for the management of muscle-invasive bladder cancer in the perioperative setting of radical cystectomy: a narrative review. <i>Translational Cancer Research</i> , 2022, 11, 908-917.	1.0	2
34	ASO Visual Abstract: Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0
35	Differential efficacy of ablation therapy versus partial nephrectomy between clinical T1a and T1b renal tumors: A systematic review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 315-330.	1.6	15
36	Circulating Tumour DNA Is a Strong Predictor of Outcomes in Patients Treated with Systemic Therapy for Urothelial Carcinoma. <i>European Urology Focus</i> , 2022, 8, 1683-1686.	3.1	4

#	ARTICLE	IF	CITATIONS
37	Incidence and outcome of salvage cystectomy after bladder sparing therapy for muscle invasive bladder cancer: a systematic review and meta-analysis. <i>World Journal of Urology</i> , 2021, 39, 1757-1768.	2.2	20
38	Nocebo Response in the Pharmacological Management of Overactive Bladder: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2021, 7, 1143-1156.	3.1	6
39	The recurrence and progression risk after simultaneous endoscopic surgery of urothelial bladder tumour and benign prostatic hyperplasia: a systematic review and meta-analysis. <i>BJU International</i> , 2021, 127, 143-152.	2.5	5
40	Primary Ta high grade bladder tumors: Determination of the risk of progression. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 132.e7-132.e11.	1.6	9
41	Impact of preoperative serum albumin-globulin ratio on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 235.e5-235.e14.	1.6	8
42	Performance of fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography imaging for lymph node staging in bladder and upper tract urothelial carcinoma: a systematic review. <i>Arab Journal of Urology Arab Association of Urology</i> , 2021, 19, 59-66.	1.5	12
43	Further Understanding of Urokinase Plasminogen Activator Overexpression in Urothelial Bladder Cancer Progression, Clinical Outcomes and Potential Therapeutic Targets. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 315-324.	2.0	5
44	Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2021, 39, 3345-3352.	2.2	18
45	The Risk of New Onset Dementia and/or Alzheimer Disease among Patients with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2021, 205, 60-67.	0.4	36
46	Diagnostic challenges and treatment strategies in the management of upper-tract urothelial carcinoma. <i>Turkish Journal of Urology</i> , 2021, 47, S33-S44.	1.3	1
47	Prognostic effect of preoperative serum albumin to globulin ratio in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>Translational Andrology and Urology</i> , 2021, 10, 609-619.	1.4	5
48	Penile Rehabilitation Strategy after Nerve Sparing Radical Prostatectomy: A Systematic Review and Network Meta-Analysis of Randomized Trials. <i>Journal of Urology</i> , 2021, 205, 1018-1030.	0.4	27
49	Benefit of Adjuvant Chemotherapy After Radical Cystectomy for Treatment of Urothelial Carcinoma of the Bladder in the Elderly – An International Multicenter Study. <i>Bladder Cancer</i> , 2021, 7, 173-185.	0.4	0
50	Oncologic impact of delaying radical prostatectomy in men with intermediate- and high-risk prostate cancer: a systematic review. <i>World Journal of Urology</i> , 2021, 39, 4085-4099.	2.2	9
51	Impact of enhanced optical techniques at time of transurethral resection of bladder tumour, with or without single immediate intravesical chemotherapy, on recurrence rate of non-muscle-invasive bladder cancer: a systematic review and network meta-analysis of randomized trials. <i>BJU International</i> , 2021, 128, 280-289.	2.5	17
52	Role of systemic immune-inflammation index in patients treated with salvage radical prostatectomy. <i>World Journal of Urology</i> , 2021, 39, 3771-3779.	2.2	10
53	Prognostic Impact of Different Gleason Patterns on Biopsy Within Grade Group 4 Prostate Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 9179-9187.	1.5	3
54	Intracorporeal versus extracorporeal urinary diversion in robot-assisted radical cystectomy: a systematic review and meta-analysis. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1587-1599.	2.2	16

#	ARTICLE	IF	CITATIONS
55	Prognostic Impact of Preoperative Plasma Levels of Urokinase Plasminogen Activator Proteins on Disease Outcomes after Radical Cystectomy. <i>Journal of Urology</i> , 2021, 206, 1122-1131.	0.4	5
56	Impact of systemic Immune-inflammatory Index on oncologic outcomes in patients treated with radical prostatectomy for clinically nonmetastatic prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 785.e19-785.e27.	1.6	14
57	Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer. <i>World Journal of Urology</i> , 2021, 39, 4355-4361.	2.2	18
58	Prognostic value of the pre-operative serum albumin to globulin ratio in patients with non-metastatic prostate cancer undergoing radical prostatectomy. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1729-1735.	2.2	3
59	Incidence, risk factors and outcomes of urethral recurrence after radical cystectomy for bladder cancer: A systematic review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 806-815.	1.6	7
60	First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021, 151, 35-48.	2.8	24
61	Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 764-773.	1.6	14
62	Adverse events of the second-line treatment for patients with locally advanced or metastatic urothelial carcinoma of the bladder: network meta-analysis. <i>Immunotherapy</i> , 2021, 13, 917-929.	2.0	1
63	Prognostic blood-based biomarkers in patients treated with neoadjuvant chemotherapy for urothelial carcinoma of the bladder: A systematic review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 471-479.	1.6	7
64	Adverse events of different chemotherapy regimens in the first-line treatment of patients with advanced or metastatic urothelial cancer: A systematic review and network meta-analysis of randomized controlled trials. <i>Seminars in Oncology</i> , 2021, 48, 181-192.	2.2	2
65	Evaluation of the Predictive Role of Blood-Based Biomarkers in the Context of Suspicious Prostate MRI in Patients Undergoing Prostate Biopsy. <i>Journal of Personalized Medicine</i> , 2021, 11, 1231.	2.5	5
66	Prognostic value of preoperative albumin to globulin ratio in patients treated with salvage radical prostatectomy for radiation recurrent prostate cancer. <i>Minerva Urology and Nephrology</i> , 2021, 73, 610-615.	2.5	6
67	Association of statins use and mortality outcomes in prostate cancer patients who received androgen deprivation therapy: a systematic review and meta-analysis. <i>Central European Journal of Urology</i> , 2021, 74, 484-490.	0.3	2
68	Impact of the preoperative modified glasgow prognostic score on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. <i>Minerva Urology and Nephrology</i> , 2021, , .	2.5	8
69	Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 936.e7-936.e14.	1.6	3
70	Impact of hospital and surgeon volumes on short-term and long-term outcomes of radical cystectomy. <i>Current Opinion in Urology</i> , 2020, Publish Ahead of Print, 701-710.	1.8	6
71	Prognostic value of testosterone for the castration-resistant prostate cancer patients: a systematic review and meta-analysis. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1881-1891.	2.2	8
72	Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1892-1900.	2.2	45

#	ARTICLE	IF	CITATIONS
73	Association of De Ritis ratio with oncological outcomes in patients with non-muscle invasive bladder cancer (NMIBC). <i>World Journal of Urology</i> , 2020, 39, 1961-1968.	2.2	10
74	Prognostic value of preoperative hematologic biomarkers in urothelial carcinoma of the bladder treated with radical cystectomy: a systematic review and meta-analysis. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1459-1474.	2.2	25
75	Management of de-novo urothelial carcinoma in transplanted patients. <i>Current Opinion in Urology</i> , 2020, 30, 467-474.	1.8	7
76	Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 539-548.	3.9	27
77	Efficacy of neoadjuvant and adjuvant chemotherapy for localized and locally advanced upper tract urothelial carcinoma: a systematic review and meta-analysis. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1037-1054.	2.2	31
78	Low compliance to guidelines in nonmuscle-invasive bladder carcinoma: A systematic review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 774-782.	1.6	26
79	The Prognostic Impact of Intraductal Carcinoma of the Prostate: A Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2020, 204, 909-917.	0.4	21
80	Bladder-preserving strategies for Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer; where are we and what will be expected?. <i>Current Opinion in Urology</i> , 2020, 30, 584-593.	1.8	5